Loading...
Loading...
EIGR| Name | Value |
|---|---|
| Revenues | 4.1M |
| Cost of Revenue | 0.1M |
| Gross Profit | 4.0M |
| Operating Expense | 26.3M |
| Operating I/L | -22.3M |
| Other Income/Expense | -0.5M |
| Interest Income | 0.7M |
| Pretax | -22.8M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -22.8M |
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in targeted therapies for rare and ultra-rare diseases. Its lead product candidate, Lonafarnib, is in Phase III clinical trials for hepatitis delta virus infection. The company also has Lambda, targeting type III interferon receptors, and Lonafarnib for progeria and progeroid laminopathies. Additionally, Avexitide is being developed for congenital hyperinsulinism and post-bariatric hypoglycemia. Eiger BioPharmaceuticals generates revenue through the development and commercialization of these innovative therapies, addressing unmet medical needs in the United States and internationally.
